Abbvie Inc
NYSE:ABBV
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
138.08
203.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ABBV stock under the Base Case scenario is 140.4 USD. Compared to the current market price of 171.73 USD, Abbvie Inc is Overvalued by 18%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Abbvie Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ABBV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
AbbVie Inc. is a global biopharmaceutical company that emerged from Abbott Laboratories in 2013, establishing itself as a key player in the healthcare sector with a strong focus on developing innovative therapies. Headquartered in North Chicago, Illinois, AbbVie specializes in immunology, oncology, neuroscience, and virology, boasting a diverse portfolio of products designed to address complex health challenges. Its flagship drug, Humira, has been a cornerstone of the company’s success, contributing significantly to its revenues since it was launched. However, with the expiration of Humira's patent, AbbVie is strategically transitioning its focus toward new treatments, including promising dr...
AbbVie Inc. is a global biopharmaceutical company that emerged from Abbott Laboratories in 2013, establishing itself as a key player in the healthcare sector with a strong focus on developing innovative therapies. Headquartered in North Chicago, Illinois, AbbVie specializes in immunology, oncology, neuroscience, and virology, boasting a diverse portfolio of products designed to address complex health challenges. Its flagship drug, Humira, has been a cornerstone of the company’s success, contributing significantly to its revenues since it was launched. However, with the expiration of Humira's patent, AbbVie is strategically transitioning its focus toward new treatments, including promising drugs in late-stage development and an expanding pipeline that aims to harness advanced technologies and unique therapeutic approaches.
As an investor, AbbVie presents an intriguing opportunity due to its robust commitment to research and development, evidenced by substantial investments that have bolstered its product lineup. The company’s proactive measures to mitigate potential revenue loss from Humira's generics include the acquisition of Allergan in 2020, which expanded its presence in aesthetic medicine and neurology with successful brands like Botox. This move not only diversified its revenue streams but also solidified AbbVie’s competitive position in the biopharmaceutical landscape. With a commitment to delivering long-term value, strong dividend performance, and a focus on innovation, AbbVie is positioned to adapt and thrive amidst the evolving industry dynamics, making it a compelling consideration for investors seeking growth in the healthcare space.
AbbVie Inc., a global biopharmaceutical company, focuses on various core business segments that drive its revenue and growth. As of my last update, here are the primary areas:
-
Immunology: This segment includes products that treat autoimmune diseases. AbbVie’s key product in this area is Humira (adalimumab), which has dominated the market for rheumatoid arthritis, psoriasis, and other conditions. With the expected loss of exclusivity for Humira in certain markets, AbbVie has been investing in new immunology therapies, such as Rinvoq (upadacitinib) and Skyrizi (risankizumab).
-
Oncology: AbbVie has a growing oncology portfolio, which includes treatments for various cancers. The company has focused its research efforts on areas such as hematologic malignancies and solid tumors. Examples of products include Venclexta (venetoclax) and Imbruvica (ibrutinib), both of which have shown significant market potential.
-
Neuroscience: This segment includes treatments for neurological disorders, such as depression and anxiety. AbbVie’s acquisition of Allergan expanded its offerings in this segment, bringing products like Botox (onabotulinumtoxinA) for a variety of therapeutic and aesthetic uses, as well as treatments for migraine and chronic pain.
-
Eye Care: Through its acquisition of Allergan, AbbVie gained a strong position in the eye care market, particularly with the product Restasis (cyclosporine), used to treat dry eye disease, and other therapies aimed at improving ocular health.
-
Virology: AbbVie also has a portfolio focused on antiviral treatments, particularly for hepatitis C. The company has developed therapies that aim to provide effective treatment options for patients living with viral infections.
-
Aesthetic Products: This segment gained prominence following the Allergan acquisition. AbbVie offers a range of aesthetic products, including dermal fillers (like Juvederm) and other treatments that cater to cosmetic needs.
These core segments represent AbbVie’s commitment to addressing significant health concerns while also focusing on innovative therapies and expanding its product portfolio through strategic acquisitions and research.
AbbVie Inc. possesses several unique competitive advantages that distinguish it from its rivals in the pharmaceutical and biotech industry:
-
Strong Portfolio of Blockbuster Drugs: AbbVie is known for its flagship product, Humira, which has generated significant revenue for the company. Even as Humira’s patent has expired, AbbVie has successfully transitioned its portfolio with drugs like Rinvoq and Skyrizi, targeting immunology.
-
Robust Pipeline: AbbVie invests heavily in research and development, which has led to a strong pipeline of new pharmaceuticals in various therapeutic areas, including oncology, immunology, and neuroscience. This diversification reduces reliance on any single product.
-
Strategic Acquisitions: The acquisition of Allergan in 2020 added a vast array of products and enhanced AbbVie’s capabilities in aesthetics, neuroscience, and women's health. This move provides cross-selling opportunities and strengthens their market position.
-
Focus on Immunology and Oncology: AbbVie has established itself as a leader in immunology and oncology treatments, with innovative therapies that are often first-in-class or best-in-class. This focus helps them maintain a competitive edge in high-growth areas.
-
Strong Intellectual Property Portfolio: AbbVie’s extensive patent portfolio protects its products from generic competition for a longer duration, securing revenue streams as competitors may be delayed in bringing alternatives to market.
-
Global Market Reach: AbbVie operates worldwide, allowing it to leverage economies of scale and pursue diverse markets. This global presence also helps mitigate risks associated with regulatory changes in specific countries.
-
Commitment to Innovation: By fostering a culture of innovation and focusing on unmet medical needs, AbbVie can stay ahead of competitors. Their substantial investment in biotechnology and personalized medicine positions them well against rivals.
-
Established Brand Reputation: AbbVie has built significant brand equity over the years, known for the quality and efficacy of its products. This reputation fosters trust among healthcare providers and patients, providing a competitive edge.
-
Manufacturing and Supply Chain Expertise: AbbVie has developed sophisticated manufacturing capabilities and a resilient supply chain. This ensures timely production and distribution of its products, enhancing reliability.
-
Partnerships and Collaborations: AbbVie often collaborates with academic institutions and biopharmaceutical companies to enhance research and development efforts. These partnerships can accelerate drug development and provide access to cutting-edge technologies.
In summary, AbbVie’s combination of a strong drug portfolio, commitment to R&D, strategic acquisitions, a focus on high-growth areas, and a robust pipeline gives it a competitive advantage in the pharmaceutical industry.
AbbVie Inc, like many biopharmaceutical companies, faces a variety of risks and challenges in the near future. Here are some of the key challenges:
-
Patent Expirations: AbbVie’s flagship product, Humira, is facing the expiration of its patents, which will allow for biosimilar competition. This can significantly affect revenue, as biosimilars typically offer lower-priced alternatives.
-
Regulatory Environment: The pharmaceutical industry is heavily regulated. Changes in regulations or increased scrutiny from regulatory bodies can impact AbbVie’s ability to bring new drugs to market or maintain compliance with existing products.
-
Market Competition: Increased competition from both established pharmaceutical companies and new entrants (including biotech firms) can pressure AbbVie’s market share and pricing strategies, especially in immunology, oncology, and other therapeutic areas.
-
Research and Development Risks: The success of AbbVie’s pipeline relies on the efficacy and safety of its drug candidates. Failures in clinical trials can lead to significant financial losses and impact investor confidence.
-
Dependence on Key Products: A substantial portion of AbbVie’s revenue comes from a limited number of products. This dependence makes the company vulnerable to fluctuations in revenue from these key products.
-
Pricing Pressure: There’s increasing scrutiny on drug pricing from governments, insurance companies, and consumers. AbbVie may face pressure to lower prices, which could hurt profit margins.
-
Economic Factors: Global economic trends can impact healthcare spending and, consequently, sales of AbbVie’s products. Economic downturns can lead to reduced healthcare budgets or changes in payer policies.
-
Supply Chain Issues: Disruptions in the supply chain, whether due to global events (e.g., pandemics, geopolitical tensions) or regulatory changes, can affect the production and distribution of AbbVie’s products.
-
Reputation and Litigation Risks: AbbVie faces litigation risks associated with its products, particularly in areas related to safety and efficacy claims. Any negative publicity can harm the company’s reputation and market position.
-
Technological Advancements: Rapid advancements in biotechnology and pharmaceuticals could lead to obsolescence of some of AbbVie’s products or require significant investment in new technologies to stay competitive.
Addressing these challenges effectively will be critical for AbbVie’s sustained growth and success in the evolving healthcare landscape.
Revenue & Expenses Breakdown
Abbvie Inc
Balance Sheet Decomposition
Abbvie Inc
Current Assets | 27.8B |
Cash & Short-Term Investments | 7.3B |
Receivables | 11.5B |
Other Current Assets | 9B |
Non-Current Assets | 115.6B |
Long-Term Investments | 267m |
PP&E | 5.1B |
Intangibles | 101.9B |
Other Non-Current Assets | 8.3B |
Current Liabilities | 43.1B |
Accounts Payable | 30.5B |
Other Current Liabilities | 12.6B |
Non-Current Liabilities | 94.3B |
Long-Term Debt | 58.5B |
Other Non-Current Liabilities | 35.8B |
Earnings Waterfall
Abbvie Inc
Revenue
|
55.5B
USD
|
Cost of Revenue
|
-18.2B
USD
|
Gross Profit
|
37.3B
USD
|
Operating Expenses
|
-21.9B
USD
|
Operating Income
|
15.4B
USD
|
Other Expenses
|
-10.4B
USD
|
Net Income
|
5.1B
USD
|
Free Cash Flow Analysis
Abbvie Inc
USD | |
Free Cash Flow | USD |
In the third quarter, AbbVie reported nearly $14.5 billion in revenue, a 4.9% operational increase, with adjusted EPS of $3, beating guidance. Their ex-HUMIRA portfolio thrived, driven by SKYRIZI and RINVOQ, expected to exceed $17 billion in sales this year. They raised full-year adjusted EPS guidance to $10.90-$10.94 and total revenue to approximately $56 billion. HUMIRA faced a 36.5% decline, but its erosion positively impacted new drug sales. The recent acquisition of Cerevel Therapeutics enhances their neuroscience pipeline. Overall, AbbVie maintains strong growth prospects with solid cash flow supporting a 5.8% dividend increase starting in 2025.
What is Earnings Call?
ABBV Profitability Score
Profitability Due Diligence
Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
ABBV Solvency Score
Solvency Due Diligence
Abbvie Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Abbvie Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABBV Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for ABBV is 210.28 USD with a low forecast of 166.65 USD and a high forecast of 252 USD.
Dividends
Current shareholder yield for ABBV is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ABBV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The firm's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
Contact
IPO
Employees
Officers
The intrinsic value of one ABBV stock under the Base Case scenario is 140.4 USD.
Compared to the current market price of 171.73 USD, Abbvie Inc is Overvalued by 18%.